Intermountain Heart Institute at Intermountain Medical Center

(801) 507-4701Map5121 S. Cottonwood StreetMurray, UT 84107

"Ongoing research is the backbone of any successful cardiovascular program. Research promotes a high level of critical thinking, which permeates how we practice medicine every day, with every patient." - Jeffrey L. Anderson, MD

Our cardiologists are committed to the research program here at Intermountain Heart Institute and frequently lead clinical investigations in cardiology and vascular medicine.  Their projects have lead to important discoveries in many areas, including:

  • Advanced cardiac imaging, including the safety of imaging modalities and early detection of heart disease.
  • Cardiac procedures, including patient safety and the development of national guidelines for percutaneous coronary interventions (PCI).
  • Cardiovascular genetics, including the development of genetic risk scores for heart disease.
  • Warfarin dosing, including alternative treatments to warfarin.
  • Diabetes and heart disease, including the risk of heart disease among patients with diabetes.

Trials Open for Enrollment

Our cardiologists are currently working with other physicians and our research program researchers on clinical trials in the following areas:

Review all cardiovascular clinical trials

Cardiovascular Genetics

Trial: GIFT
Long Title: Protocol for Genetics-Informatics Trial (GIFT) of Warfarin to Prevent DVT
Principal Investigator: Jeffrey Anderson, MD
Sponsor: National Institutes of Health
Description: The objective of the GIFT trial is to determine ways to improve the safety and efficacy of the medication warfarin. All of the participants in this study will undergo genetic testing and will be randomly assigned to one of two medication dosing groups. Half of the patients in this study will have the amount of warfarin prescribed to them determined by their doctor in the usual way, based on their health history alone. The other half of the patients will have their genetic test results used in combination with their health history to determine the amount of warfarin they will receive. All patients will be followed for about one month. The study will determine if genetic testing assists doctors in prescribing the most effective amount of medication.
For More Information: (801) 507-4701

Trial: Intermountain Heart Collaborative Study
Sponsor: This is original research from the Heart Institute at Intermountain Medical Center. There is no corporate sponsorship.
Description: Much is already known about the relationships between heart disease and smoking, high blood pressure, high cholesterol, and diabetes. However, scientists are still trying to discover the exact role of genetics and other biological influences on how this disease progresses.

Over the past 17 years, we have collected more than 20,000 DNA samples from patients who have been evaluated for heart disease at LDS Hospital and Intermountain Medical Center. We call it the Intermountain Heart Collaborative Study – a tremendous resource for discovering the underlying factors of heart disease. We are continuing to expand and increase our enrollment into this important registry. Over the past three years alone, the use of this registry has resulted in the publication of more than 40 research papers, all of which were published in major international scientific journals! All patients who are 18 years of age or older and enter the cardiac catheterization lab at Intermountain Medical Center are eligible to participate.
For More Information: (801) 507-4701

Diabetes and Heart Disease

Trial: FACTOR 64
Long Title: Screening for Asymptomatic Obstructive Coronary Artery Disease Among High-Risk Diabetic Patients Using CT Angiography: A Randomized Control Trial
Principal Investigator: Brent Muhlestein, MD
Sponsor: Toshiba Medical Systems, Bracco Diagnostics, Intermountain Research and Medical Foundation, formerly the Deseret Foundation, and Intermountain Healthcare
Description: This study is evaluating patients with diabetes and no prior, documented evidence of cardiovascular disease. Half of the participants in this study will be randomly chosen to undergo a 64 multidetector Coronary CT or calcium score CT to evaluate their risk for heart disease. The other half of the patients will continue to receive standard treatment for their symptoms by their regular health care providers. The purpose of this study is to determine if testing diabetic patients before they have symptoms of heart disease will result in early identification and treatment of disease, and if the early treatment decreases heart attacks and death caused by coronary artery disease.
For More Information: (801) 507-4701

Carotid Artery Stenosis

Trial: SAPHIRE WW
Long Title: Stenting and Angioplasty with Protection in Patients at High-Risk for Endarterectomy
Principal Investigator: James Burke, MD
Sponsor: Cordis Corporation
Description: The purpose of this study is to collect more information on how well patients do after carotid stenting for treatment of their carotid artery stenosis. The common treatment for this condition includes a surgery called carotid endarterectomy. Patients who are at high risk for the surgery may be eligible to participate in this study. All patients will be followed for 30 days following their treatment.
For More Information: (801) 507-4701

High Blood Pressure

Trial: SPRINT
Long Title: Systolic Blood Pressure Intervention Trial
Sponsor: National Institutes of Health
Description: SPRINT is a clinical trial designed to test whether a treatment program aimed at reducing systolic blood pressure to a lower goal than currently recommended will reduce cardiovascular disease. Over 9000 patients will participate in this study; participants must be age 50 or older, have a systolic blood pressure of equal or greater than 130mm Hg, and at least one other risk factor for heart disease. Patients will be randomly assigned to one of two blood pressure target groups. Their doctor will prescribe medications to help them reach and maintain their target pressure. This study will help determine if maintaining a lower target blood pressure level decreases cardiovascular events, slows the worsening of chronic kidney disease, and slows age-related declines in cognition.
For More Information: (801) 507-4701

Copyright © , Intermountain Healthcare, All rights reserved.